Overview of This Study:

This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global human microbiome market.

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The human microbiome market's size was estimated through various secondary research approaches and triangulated with inputs from primary research.

Expected Growth in Revenue During Forecst Period:

The human microbiome market is projected to reach USD 1,598 million by 2028 from USD 894 million in 2025, at a CAGR of 21.3% from 2025 to 2028.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Growth Influencing Factors:

Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is also expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market's growth.

Global Leaders:

The major players in the human microbiome market include Enterome Bioscience (France), Seres Therapeutics (US), 4D Pharma (UK), and Ferring Pharmaceuticals (Switzerland). Various growth strategies have been adopted by these players, such as agreements, collaborations, partnerships, and acquisitions to increase their presence in the global human microbiome market.

Recent Developments:

# In 2020, 4D pharma merged with Longevity Acquisition Corporation to gain a NASDAQ listing. In turn, Longevity will support and accelerate the ongoing development of 4D pharma’s Live Biotherapeutic. Live Biotherapeutics is a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment, or cure of a disease.

# In 2020, BiomX collaborated with Boehringer Ingelheim to utilize the microbiome-based biomarker discovery platform to potentially identify biomarkers associated with patient phenotypes in Inflammatory Bowel Disease (IBD).

# In 2019, Seres collaborated with AstraZeneca to get a better understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds

Challenge: Lack of expertise and inadequate research

The concept of bio-ecologic control of the gut has recently been proposed as a novel method of improving human health. This approach involves the use of probiotics and prebiotics. However, the mechanisms by which prebiotic bio-ecologic strategies exert their beneficial health effects remain largely unknown. It is also unknown how bacteria interact with each other or with the human body to cause or prevent certain diseases. Considering the large variability in the human intestinal ecosystem, these approaches are unlikely to fulfill their potential until the exact profile of an individual’s microbiome can be determined. Collecting, sequencing, and analyzing DNA from thousands of microbial species living in and on humans requires an interdisciplinary team with the knowledge of clinical ethics, engineering, and bioinformatics.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

The Asia Pacific region is the fastest growing region of human microbiome research spending market in 2019

On the basis of region, the global human microbiome research spending market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the global human microbiome research spending market in 2019. In 2019, the Asia Pacific region is estimated to grow at the highest CAGR in the human microbiome research spending from 2020-2025. Factors such as increasing focus on microbiome research and initiatives taken by public and private organizations to increase awareness regarding microbiome therapeutics, are driving the growth of the human microbiome market in the Asia Pacific (APAC) region.

Enterome Bioscience (France) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat microbiome-associated diseases with a focus on IBDs, Crohn’s, and cancer (glioblastoma, colon, pancreatic, lung, and breast) indications. To sustain its position in the human microbiome market, ENTEROME adopts various organic and inorganic growth strategies.

The company has been consistently entering into agreements and partnerships with strong biopharmaceutical players, which will help it to expedite drug development for cancer and GI disorders. In 2020, the company received funds of USD 52.6 million from investors, including SymBiosis, LLC (US), a microbiome-focused investment vehicle, and Takeda Pharmaceutical Company Limited (Japan) for the progress of clinical development of its therapeutic pipeline. This pipeline includes the first clinical trials of EO2401, a novel OncoMimic cancer immunotherapy.

Seres Therapeutics (US) is one of the emerging players operating in this market. The company is engaged in developing a range of novel therapeutic products based on the human microbiome. To sustain its position in the human microbiome market, Seres Therapeutics focuses on its products offered for the market. The company’s microbiome therapeutics platform allows to significantly reduces the time typically required to advance therapeutics to the clinic, and ultimately, to the market. The company’s SER-109 program for the treatment of recurrent C difficile infection is anticipated to be the first-ever FDA-approved microbiome therapy. This has helped the company to strengthen its market position in high-growth niche opportunities.

R&D Capabilities: Seres Therapeutics focuses on collaborations to expand its market position in the human microbiome market. In March 2019, Seres collaborated with AstraZeneca to advance the mechanistic understanding of the microbiome in augmenting the efficacy of cancer immunotherapy. Under the agreement, AstraZeneca will pay the company a total of USD 20,000 in three equal instalments.

Read the Detailed Report@
https://www.marketsandmarkets.com/Market-Reports/human-microbiome-market-37621904.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]